Eris Lifesciences: Second Corrigendum to Postal Ballot Notice Issued
Eris Lifesciences Limited issued a second corrigendum to its Postal Ballot Notice dated November 24, 2025. An updated valuation report dated December 17, 2025, has been issued, removing references to DCF methodology. E-voting ends December 24, 2025. No change in share valuation or swap ratio.
This is a corrigendum clarifying an existing process (postal ballot) and updating a valuation report without altering the core financial terms or company control. Therefore, the market impact is expected to be minimal.
The announcement is a procedural update regarding a postal ballot notice and valuation report. It clarifies information without introducing new material financial events or changes that would significantly impact the company's valuation or market position.
Eris Lifesciences Limited has issued a second corrigendum to its Postal Ballot Notice dated November 24, 2025. This corrigendum, dated December 17, 2025, is being dispatched electronically to shareholders.
The primary purpose of this second corrigendum is to inform members about an updated valuation report dated December 17, 2025. This updated report supersedes the revised valuation report from December 5, 2025, which was referenced in the first corrigendum. The valuer has updated the report to remove all references to the Discounted Cash Flow (DCF) methodology previously used, in response to queries from stock exchanges.
The e-voting period for the postal ballot commenced on Tuesday, November 25, 2025, at 9:00 a.m. IST and will conclude on Wednesday, December 24, 2025, at 5:00 p.m. IST. Shareholders who have already cast their votes and wish to modify them in light of the new information can do so by emailing the scrutinizer at ravi@ravics.com on or before 5:00 p.m. IST on December 24, 2025.
Importantly, the company states that there is no change in the fair valuation of Eris Lifesciences Limited's equity shares or the proposed swap ratio due to this updated valuation report. The corrections made do not result in any change in management control. All other terms and contents of the original Notice and the first Corrigendum remain unchanged.
What to do with a filing like this
Eris Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Eris Lifesciences Limited. Read the original for the full detail.